Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
Top Cited Papers
Open Access
- 18 February 2020
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3), 587-594
- https://doi.org/10.1210/clinem/dgaa048
Abstract
Objective The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab. Conclusions We reviewed findings from the meta-analysis and primary clinical trials assessing the efficacy of romosozumab, a monoclonal antibody targeting sclerostin, for the prevention of fractures and concluded that this agent can be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture. The romosozumab label has a boxed warning, recommending careful consideration by the treating clinician as to cardiovascular risk profile in the individual woman who might receive this agent, since clinical trial data from an active comparator study show an imbalance in serious cardiovascular adverse events between romosozumab and alendronate.Keywords
This publication has 13 references indexed in Scilit:
- Novel actions of sclerostin on boneJournal of Molecular Endocrinology, 2019
- One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension StudyJournal of Bone and Mineral Research, 2018
- Romosozumab or Alendronate for Fracture Prevention in Women with OsteoporosisThe New England Journal of Medicine, 2017
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trialThe Lancet, 2017
- Romosozumab Treatment in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2016
- Romosozumab in Postmenopausal Women with Low Bone Mineral DensityThe New England Journal of Medicine, 2014
- Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up studyOsteoporosis International, 2012
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008